Friday, 29 March 2024


VolitionRx commences lung cancer clinical study with Fosun in China

22 July 2019 | News

The parties have commenced a clinical study in China in lung cancer.

Belgium based VolitionRx Limited has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. to help introduce the Nu.Q(TM) platform to China. Based on recent promising proof-of-concept data using Volition's product-grade Nu.Q assays, the parties have commenced a clinical study in China in lung cancer.

Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition, commented: "We are happy to have executed this agreement with Fosun Long March and are delighted that the clinical study is already underway and expected to be completed by the end of this year."

Dr. Yuejian Zhang, Chairman of Fosun Long Marchremarked: "We were impressed with Volition's preliminary data, particularly in lung cancer, and are happy to have started work on these initial clinical studies. Whilst China represents a little under 20% of the world's population, it accounted for almost 24% of cancer diagnoses and 30% of cancer-related deaths worldwide in 2018, almost a third of which were due to lung cancer and colorectal cancer. We look forward to completing this important study and working together with Volition to launch Nu.Q in China."

"The need for a simple, easy to use, cost effective test for cancer is truly universal and we hope very much that our Nu.Q tests can help revolutionize the way cancer is diagnosed worldwide," commented Cameron Reynolds, Chief Executive Officer of Volition. "We see Asia, and particularly lung cancer in China, as a key market for Volition. We are excited about the commencement of our work in China and look forward to a successful collaboration with Fosun Long March."

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account